Analyst firms · Raymond James · BIIB

Raymond James BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Raymond James rates Biogen Inc. (BIIB) Mkt Perform with a $283 price target, as of its latest action on Oct 10, 2024. It has published 3 rating actions on BIIB since December 2021, including 1 upgrade and 0 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

Current rating
Mkt Perform
Price target
$283
Median target, all firms
$231.50
Actions on BIIB
3

Every Raymond James rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Raymond James and BIIB

What is Raymond James's price target for BIIB?
Raymond James's latest stated price target for Biogen Inc. (BIIB) is $283, from its action on Dec 7, 2023.
What is Raymond James's rating on BIIB?
Raymond James rates BIIB Mkt Perform, a neutral rating, as of Oct 10, 2024.
When did Raymond James last change its view on BIIB?
On Oct 10, 2024, Raymond James resumes coverage at Mkt Perform.
How does Raymond James's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

More BIIB rating histories

All Raymond James ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.